These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12862188)

  • 1. Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada.
    Giacomini M; Miller F; Browman G
    Int J Technol Assess Health Care; 2003; 19(2):301-16. PubMed ID: 12862188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.
    Giacomini M
    Milbank Q; 2005; 83(2):193-223. PubMed ID: 15960769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment in Australia: challenges ahead.
    Jackson TJ
    Med J Aust; 2007 Sep; 187(5):262-4. PubMed ID: 17767428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The many meanings of deinsuring a health service: the case of in vitro fertilization in Ontario.
    Giacomini M; Hurley J; Stoddart G
    Soc Sci Med; 2000 May; 50(10):1485-500. PubMed ID: 10741583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers.
    Adair A; Hyde-Lay R; Einsiedel E; Caulfield T
    BMC Med Ethics; 2009 Jun; 10():6. PubMed ID: 19538750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The review process used by US health care plans to evaluate new medical technology for coverage.
    Steiner CA; Powe NR; Anderson GF; Das A
    J Gen Intern Med; 1996 May; 11(5):294-302. PubMed ID: 8725978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insurance coverage for experimental technologies.
    Steinberg EP; Tunis S; Shapiro D
    Health Aff (Millwood); 1995; 14(4):143-58. PubMed ID: 8690340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic considerations for health insurance coverage of emerging genetic tests.
    Giacomini M; Miller F; O'Brien BJ
    Community Genet; 2003; 6(2):61-73. PubMed ID: 14560066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The which-hunt: assembling health technologies for assessment and rationing.
    Giacomini MK
    J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coverage with evidence development: the Ontario experience.
    Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How health economic evaluation (HEE) contributes to decision-making in public health care: the case of Brazil.
    Elias FT; Araújo DV
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):405-12. PubMed ID: 25444299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of medical technologies in Sweden.
    Jönsson B
    Soc Sci Med; 1997 Aug; 45(4):597-604. PubMed ID: 9226784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice.
    Abelson J; Giacomini M; Lehoux P; Gauvin FP
    Health Policy; 2007 Jun; 82(1):37-50. PubMed ID: 16996637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The National Institute for Clinical Excellence (NICE)].
    Rothgang H; Niebuhr D; Wasem J; Gress S
    Gesundheitswesen; 2004 May; 66(5):303-10. PubMed ID: 15141350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations.
    Williams-Jones B; Burgess MM
    Kennedy Inst Ethics J; 2004 Jun; 14(2):115-42. PubMed ID: 15281186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation in support of national health policy: the case of The Netherlands.
    Elsinga E; Rutten FF
    Soc Sci Med; 1997 Aug; 45(4):605-20. PubMed ID: 9226785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology assessment, coverage decisions, and conflict: the role of guidelines.
    Sheingold SH
    Am J Manag Care; 1998 Sep; 4 Spec No():SP117-25. PubMed ID: 10185988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare and cost-effectiveness analysis.
    Neumann PJ; Rosen AB; Weinstein MC
    N Engl J Med; 2005 Oct; 353(14):1516-22. PubMed ID: 16207857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.